Status:
COMPLETED
Effects of L-arginine Supplementation in Adults With Moderate to Severe Asthma
Lead Sponsor:
University of California, Davis
Collaborating Sponsors:
National Institutes of Health (NIH)
National Center for Research Resources (NCRR)
Conditions:
Asthma
Eligibility:
All Genders
18-90 years
Phase:
PHASE2
Brief Summary
Nitric oxide is an important marker of airway inflammation in asthma. Nitric oxide may have a protective role in patients with moderate to severe asthma. The investigators believe that a natural amino...
Detailed Description
The primary objective of this 3 month clinical study is to determine if supplemental L-arginine can decrease the number of asthma exacerbations in patients with severe asthma. L-arginine, a natural am...
Eligibility Criteria
Inclusion
- Moderate to severe persistent asthma
- Subject is stable on same asthma medications for at least one month
- If the subject is a woman of child-bearing age, a negative pregnancy test
Exclusion
- Less than 18 yrs/ age
- Baseline Forced Expiratory Volume in 1 second (FEV1) \<40% predicted
- Known or suspected allergy to L-arginine
- Pregnant women, nursing women, or women actively trying to achieve pregnancy
- Current smokers
- Subjects with more than a 15 pack-year history of smoking
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00280683
Start Date
December 1 2004
End Date
December 1 2008
Last Update
May 30 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, Davis General Clinical Research Center
Sacramento, California, United States, 95817